Innovate Biopharmaceuticals, Inc. (INNT) Rises to $24.87

June 29, 2018 - By Amber Marburger

Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) increased significantly to $24.87. Barchart.com reported it on Jun, 29. It has $638.92M MC. The company’s valuation will be $31.95 million more at $26.11 PT.

For more Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) news announced recently go to: Benzinga.com, Benzinga.com, Globenewswire.com, Benzinga.com or Globenewswire.com. The titles are as follows: “20 Stocks Moving In Thursday’s Pre-Market Session” announced on June 28, 2018, “40 Stocks Moving In Wednesday’s Mid-Day Session” on June 27, 2018, “Innovate Biopharmaceuticals Scheduled to Present at the Jefferies Global Healthcare Conference in New York on …” with a publish date: May 31, 2018, “44 Biggest Movers From Yesterday” and the last “Innovate Biopharmaceuticals Announces Appointment of Saira Ramasastry to Board of Directors and Resignation of …” with publication date: June 13, 2018.

Innovate Biopharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing autoimmune and inflammation therapeutics.The company has $638.92 million market cap. The Company’s late-stage clinical pipeline focuses on addressing unmet needs in diseases, such as celiac disease, inflammatory bowel disease , and nonalcoholic steatohepatitis (NASH).Last it reported negative earnings. The company's lead drug candidate, larazotide acetate (INN-202), has successfully met its primary endpoint in a Phase 2b efficacy clinical trial for celiac disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: